Sanofi Pasteur opens $101M R&D facility
The facility is now Sanofi Pasteur's North American Centre of Excellence for analytical and bioprocessing research.
Toronto—France-based vaccine maker Sanofi Pasteur Ltd. has opened a $101-million vaccine research and development facility at the firm’s Connaught Campus in north Toronto.
The facility is now Sanofi Pasteur’s North American Centre of Excellence for analytical and bioprocessing research, development and manufacturing of vaccines that protect public health .
The province of Ontario contributed $13.9 million to the project through its Biopharmaceutical Investment Program.
“Sanofi Pasteur is a valued partner in our commitment to health care in Ontario,” said Premier Dalton McGuinty. “This impressive new building houses some of the most exciting talent anywhere, doing some of the most vital research in the world. We congratulate Sanofi Pasteur and look forward to new breakthroughs and new jobs.”
The new R&D facility, known internally as “Building 95,” will help the company retain 300 vaccine research positions and bring many of the company’s accomplished scientists and state-of-the-art technologies under one roof. Its North American Centre of Excellence designation means the critical mass of scientific expertise at Connaught Campus is playing a lead role in advancing Sanofi Pasteur’s global vaccine pipeline.
The Toronto site manufactures “…vaccines vital to public health” with 94 per cent of its vaccine production delivered to more than 90 countries around the world. Indeed, 20 per cent of global sales at Sanofi Pasteur are generated by vaccines manufactured at the Connaught Campus.
In this video, Mark Lievonen, president of Sanofi Pasteur Ltd., speaks on protecting intellectual property in Canada.